External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1475-2840
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease ; volume:20 ; number:1 ; day:8 ; month:9 ; year:2021 ; pages:1-10 ; date:12.2021
Cardiovascular diabetology ; 20, Heft 1 (8.9.2021), 1-10, 12.2021

Urheber
Smidt, Lisanne C. A.
Visseren, Frank L. J.
Ranitz-Greven, Wendela L. de
Nathoe, Hendrik M.
Kappelle, L. Jaap
Borst, Gert J. de
Valk, Harold W. de
Westerink, Jan
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12933-021-01373-9
URN
urn:nbn:de:101:1-2021112220110355884758
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:25 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Smidt, Lisanne C. A.
  • Visseren, Frank L. J.
  • Ranitz-Greven, Wendela L. de
  • Nathoe, Hendrik M.
  • Kappelle, L. Jaap
  • Borst, Gert J. de
  • Valk, Harold W. de
  • Westerink, Jan
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Updates on cardiovascular outcome trials in diabetes

Updates on cardiovascular outcome trials in diabetes

Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

Cardiovascular development: towards biomedical applicability : T-box factors determine cardiac design

Cardiovascular development: towards biomedical applicability : T-box factors determine cardiac design

Adaptive designs for clinical trials in cardiovascular diseases

Adaptive designs for clinical trials in cardiovascular diseases

Current perspectives on cardiovascular outcome trials in diabetes

Current perspectives on cardiovascular outcome trials in diabetes

Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors

Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors

Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials

Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials

Verbundene Objekte